Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Cancer Biol Ther. 2009 May 18;8(10):939–950. doi: 10.4161/cbt.8.10.8213

Figure 6. Co-treatment with decitabine and panobinostat, or 17-DMAG inhibits clonogenic survival greater than treatment with the single agents alone.

Figure 6

A. K562 cells were treated with the indicated doses of DAC and/or panobinostat for 48 hours. Following treatment the cells were washed and plated in methocult media for 7 days. (*) represents values significantly less than those following treatment with either agent alone at the indicated concentrations (p=0.04 and p=0.007, respectively). B–C. K562 cells were treated with the indicated doses of DAC and/or 17-DMAG for 48 hours. The cells were washed and plated as before. (*) represents values significantly less than those following treatment with either agent alone at the indicated concentrations (p=0.04). D. K562 cells were treated with the indicated concentrations of panobinostat and/or 17-DMAG for 48 hours. Following treatment the cells were washed and plated in methocult media for 7 days.